A Phase III Study Comparing Etoposide and Cisplatin (EP) With Irinotecan and Cisplatin (IP) Following EP Plus Concurrent Accelerated Hyperfractionated Thoracic Irradiation (EP/TRT) for Limited-Stage Small-Cell Lung Cancer : JCOG0202-MF
A Phase III Study Comparing Etoposide and Cisplatin (EP) With Irinotecan and Cisplatin (IP) Following EP Plus Concurrent Accelerated Hyperfractionated Thoracic Irradiation (EP/TRT) for Limited-Stage Small-Cell Lung Cancer : JCOG0202-MF
To evaluate the role of 3 cycles of irinotecan and cisplatin for patients with limited-stage small-cell lung cancer who received one course of etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic irradiation.
The Japan Clinical Oncology Group (JCOG) previously conducted a randomized phase III trial comparing irinotecan and cisplatin (IP) with EP in patients with extensive-stage SCLC. The response rate and overall median survival were significantly better for IP, i.e. 84.4% and 12.8 months with IP, versus 67.5% and 9.4 months with EP, respectively. The 2-year survival rates were 19.5% for IP and 5.2% for EP (7). These encouraging results prompted us to explore the use of IP in LSCLC.
Inclusion Criteria:
Exclusion Criteria:
Matsuyama,Horinouchi,13, Ehime 790-0007, Japan
Shibukawa,Kanai,2854, Gunma 377-8511, Japan
Asahikawa,Hanasaki,7-4048, Hokkaido 070-8644, Japan
Sapporo,Shiroishi-ku,Kikusui,4-2-3-54, Hokkaido 003-0804, Japan
Nishi-ibarakigun,Tomobemachi,Koibuchi,6528, Ibaraki 309-1793, Japan
Yokohama,Asahi-ku,Nakao,1-1-2, Kanagawa 241-0815, Japan
Yokohama,Hodogaya-ku,Okazawa-cho,56, Kanagawa 240-8555, Japan
Kumamoto,Honjo,5-16-10, Kumamoto 860-0811, Japan
Habikino,Habikino,3-7-1, Osaka 583-8588, Japan
Osaka,Abeno-ku,Asahi-machi,1-5-7, Osaka 545-0051, Japan
Osaka,Higashinari-ku,Nakamichi,1-3-3, Osaka 537-8511, Japan
Osaka,Sumiyoshi-ku,Bandai-higashi,3-1-56, Osaka 558-8558, Japan
Sakai,Nagasone,1180, Osaka 591-8555, Japan
Toyonaka,Toneyama,5-1-1, Osaka 560-8552, Japan
Kita-adachi,Ina,Komuro,818, Saitama 362-0806, Japan